首页> 外文OA文献 >Erratum: The efficacy and safety of anti‐PD‐1/PD‐L1 antibodies combined with chemotherapy or CTLA4 antibody as a first‐line treatment for advanced lung cancer

【2h】

Erratum: The efficacy and safety of anti‐PD‐1/PD‐L1 antibodies combined with chemotherapy or CTLA4 antibody as a first‐line treatment for advanced lung cancer

机译：错误：抗PD-1 / PD-L1抗体的疗效和安全性与化疗或CTLA4抗体相结合，作为晚期肺癌的一线治疗

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Bo Zhang; Qiong Wu;
展开▼
作者单位

展开▼
年度 2018
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. The efficacy and safety of anti-PD-1/PD-L1 antibodies combined with chemotherapy or CTLA4 antibody as a first-line treatment for advanced lung cancer (vol 142, pg 2344, 2018) [J] . Zhang Bo, Wu Qiong International Journal of Cancer =: Journal International du Cancer . 2019,第7期

机译：抗PD-1 / PD-L1抗体的疗效和安全性与化疗或CTLA4抗体相结合，作为晚期肺癌的一线治疗（Vol 142，PG 2344,2018）
2. The efficacy and safety of anti‐ PD PD ‐1/ PD‐L PD‐L 1 antibodies combined with chemotherapy or CTLA CTLA 4 antibody as a first‐line treatment for advanced lung cancer [J] . Xu Xiaoling, Huang Zhiyu, Zheng Lei, International Journal of Cancer =: Journal International du Cancer . 2018,第11期

机译：抗PD -1 / PD-L PD-1抗体的功效和安全性与化疗或CTLA CTLA 4抗体相结合，作为晚期肺癌的一线治疗
3. P2.07-057 Anti-PD-1/PD-L1 Antibodies Combine with Chemotherapy or CTLA4 Antibodies for First-Line Treatment of Advanced Lung Cancer [J] . Y. Fan, X. Xu Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2017,第11期

机译：P2.07-057抗PD-1 / PD-L1抗体与化疗或CTLA4抗体结合，用于一线治疗晚期肺癌
4. ~(177)Lu-DOTA-J591 MONOCLONAL ANTIBODY: CHEMISTRY, TOXICITY, DOSIMETRY AND CLINICAL EFFICACY: RIT OF PROSTATE CANCER USING ~(177)LU-J591 ANTI-PSMA ANTIBODY [C] . S.J. GOLDSMITH, S. VALLABHAJOSULA, M.I. MILOWSKY, Trends in Radiopharmaceuticals(ISTR-2005) . 2007

机译：〜（177）Lu-DOTA-J591单克隆抗体：化学，毒性，剂量和临床疗效：使用〜（177）LU-J591抗-PSMA抗体的前列腺癌
5. T-Cell Checkpoints, and the PD-1/L1 Pathway in Particular, are a Mode of Resistance to DNA Vaccination and Rational Combination Therapies Improve Vaccine Efficacy for the Treatment of Prostate Cancer. [D] . Rekoske, Brian. 2017

机译：T细胞检查点以及PD-1 / L1途径尤其是对DNA疫苗产生抗药性的一种方式，合理的联合疗法可提高疫苗治疗前列腺癌的功效。
6. The efficacy and safety of anti-PD-1/PD-L1 antibodies for treatment of advanced or refractory cancers: a meta-analysis [O] . Tengfei Zhang, Jing Xie, Seiji Arai, 2016

机译：抗PD-1 / PD-L1抗体治疗晚期或难治性癌症的功效和安全性：一项荟萃分析
7. The efficacy and safety of anti-PD-1/PD-L1 antibodies for treatment of advanced or refractory cancers: a meta-analysis [O] . Tengfei Zhang, Jing Xie, Seiji Arai, 2016

机译：抗PD-1 / PD-L1抗体治疗晚期或难治性癌症的疗效和安全性：META分析

Erratum: The efficacy and safety of anti‐PD‐1/PD‐L1 antibodies combined with chemotherapy or CTLA4 antibody as a first‐line treatment for advanced lung cancer

著录项

相似文献

相关主题

期刊订阅